Edesa Biotech
EDSA
26 hedge funds and large institutions have $2.05M invested in Edesa Biotech in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1,952% more capital inflows, than outflows
Capital inflows: $983K | Capital outflows: $47.9K
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
24% more funds holding
Funds holding: 21 → 26 (+5)
2.87% more ownership
Funds ownership: 8.35% → 11.22% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$586K |
| 2 |
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$247K |
| 3 |
Two Sigma Investments
New York
|
+$39.8K |
| 4 |
Renaissance Technologies
New York
|
+$26.1K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$32.9K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$11.8K |
| 3 |
Morgan Stanley
New York
|
-$2.96K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$146 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$84 |
EDSA Hedge Fund Activity: Q1 2023 in Review
26 of the 6,290 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q1 2023, worth a combined $2.05M — down 41% from $3.49M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EDSA positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Velan Capital Investment Management, adding an estimated $586K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $32.9K sold.
- 26 institutional investors held Edesa Biotech (EDSA) as of Q1 2023, up from 21 in Q4 2022.
- Funds reported $2.05M of Edesa Biotech stock for Q1 2023, down 41% quarter-over-quarter.
- 7 funds opened new Edesa Biotech positions in Q1 2023 and 2 closed out, a net change of +5 holders.
- The largest Edesa Biotech buyer in Q1 2023 was Velan Capital Investment Management, an estimated $586K added.
- The largest Edesa Biotech seller in Q1 2023 was Susquehanna International Group, an estimated $32.9K sold.
Based on aggregated 13F filings for Q1 2023.